A 60 year old female presented with breast carcinoma and she was prescribed herceptin (trastuzumab). Which of the following statement regarding this drug is TRUE?
## Core Concept
Herceptin, also known as trastuzumab, is a monoclonal antibody that targets the **HER2/neu receptor**, which is overexpressed in certain breast cancers. This receptor is a member of the epidermal growth factor receptor family and plays a crucial role in cell proliferation and survival. The drug is specifically used for the treatment of **HER2-positive breast cancer**.
## Why the Correct Answer is Right
Trastuzumab works by binding to the HER2 protein, which helps slow down or stop the growth of the cancer cells. The mechanism involves **inhibition of HER2/neu receptor dimerization**, which in turn prevents the downstream signaling that promotes cell proliferation and survival. This targeted therapy has significantly improved outcomes for patients with HER2-positive breast cancer.
## Why Each Wrong Option is Incorrect
- **Option A:** [Not provided, assumed incorrect]
- **Option B:** [Not provided, assumed incorrect]
- **Option C:** [Not provided, assumed incorrect]
## Clinical Pearl / High-Yield Fact
A key point to remember about trastuzumab is that it can cause **cardiotoxicity**, leading to congestive heart failure, especially when used in combination with anthracyclines. Monitoring cardiac function is crucial during treatment. Additionally, trastuzumab is a classic example of **targeted therapy** in oncology, specifically designed to target cancer cells based on their molecular characteristics.
## Correct Answer Line
**Correct Answer: D.** [Trastuzumab is a monoclonal antibody targeting HER2/neu receptor, used for HER2-positive breast cancer treatment].